EUVIMEDEUVIMED entdecken
EvaluationsstudieOpen Access · CC BY 4.0

NT-proBNP in systemic right ventricles: a new cutoff level for risk stratification?

Fabian Tran, Francisco Javier Ruperti-Repilado, Philip Haaf, Pedro Lopez-Ayala, Matthias Greutmann, Markus Schwerzmann, Judith Bouchardy, Harald Gabriel, Dominik Stambach, Juerg Schwitter, Kerstin Wustmann, Michael Freese und 2 weitere

Revista Española de Cardiología (English Edition) · 2025

DOI: 10.1016/j.rec.2024.05.006 ↗

Kurz gefasst

Evaluationsstudie in der Zeitschrift Revista Española de Cardiología (English Edition), 2025. Verfasst von Fabian Tran und 13 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Research Institute Basel, University Hospital Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: Heart Ventricles, Natriuretic Peptide, Brain, Peptide Fragments, Ventricular Dysfunction, Right. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss National Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION AND OBJECTIVES: The role of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in the risk prediction of patients with systemic right ventricles (sRV) is not well defined. The aim of this study was to analyze the prognostic value of NT-proBNP in patients with an sRV. METHODS: The prognostic value of NT-proBNP was assessed in 98 patients from the SERVE trial. We used an adjusted Cox proportional hazards model, survival analysis, and c-statistics. The composite primary outcome was the occurrence of clinically relevant arrhythmia, heart failure, or death. Correlations between baseline NT-proBNP values and biventricular volumes and function were assessed by adjusted linear regression models. RESULTS: The median age [interquartile range] at baseline was 39 [32-48] years and 32% were women. The median NT-proBNP was 238 [137-429] ng/L. Baseline NT-proBNP concentrations were significantly higher among the 20 (20%) patients developing the combined primary outcome compared with those who did not (816 [194-1094] vs 205 [122-357]; P=.003). In patients with NT-proBNP concentrations> 75th percentile (> 429 ng/L), we found an exponential increase in the sex- and age-adjusted hazard ratio for the primary outcome. The prognostic value of NT-proBNP was comparable to right ventricular ejection fraction and peak oxygen uptake on exercise testing (c-statistic: 0.71, 0.72, and 0.71, respectively). CONCLUSIONS: In patients with sRVs, NT-proBNP concentrations correlate with sRV volumes and function and may serve as a simple tool for predicting adverse outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart VentriclesNatriuretic Peptide, BrainPeptide FragmentsVentricular Dysfunction, RightVentricular Function, RightAdultFemaleHumansMaleMiddle AgedBiomarkersEchocardiographyFollow-Up StudiesPrognosisRisk AssessmentStroke VolumeSurvival RateRandomized Controlled Trials as TopicMulticenter Studies as TopicSecondary Data Analysis

Stichwörter der Autor:innen

BiomarcadoresBiomarkersCardiopatías congénitas del adultoCongenital heart diseaseHeart FailureInsuficiencia cardiacaTransposición de las grandes arteriasTransposition of the great arteries

Substanzen

BiomarkersNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)

Autor:innen und Institutionen

  • Cardiovascular Research Institute Basel, University Hospital Basel, Basel, Switzerland.
  • Cardiovascular Research Institute Basel, University Hospital Basel, Basel, Switzerland; Division of Cardiology, University Hospital of Basel, University of Basel, Basel, Switzerland.
  • Division of Cardiology, University Hospital of Basel, University of Basel, Basel, Switzerland.
  • Department of cardiology University Heart Center, University of Zurich, Zurich, Switzerland.
  • University Clinic of Cardiology, Center for Congenital Heart Disease, Inselspital, University Hospital, University of Bern, Bern, Switzerland; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Canada.
  • Division of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland; Division of Cardiology, Hôpitaux Universitaires de Genève (HUG), Genève, Switzerland.

Förderung

  • Swiss National Science Foundation

Zitieren

APA

Tran, F., Ruperti-Repilado, F. J., Haaf, P., Lopez-Ayala, P., Greutmann, M., Schwerzmann, M., Bouchardy, J., Gabriel, H., Stambach, D., Schwitter, J., Wustmann, K., Freese, M., Mueller, C., & Tobler, D. (2025). NT-proBNP in systemic right ventricles: a new cutoff level for risk stratification?. Revista Española de Cardiología (English Edition). https://doi.org/10.1016/j.rec.2024.05.006

Vancouver

Tran F, Ruperti-Repilado FJ, Haaf P, Lopez-Ayala P, Greutmann M, Schwerzmann M, et al. NT-proBNP in systemic right ventricles: a new cutoff level for risk stratification?. Revista Española de Cardiología (English Edition). 2025. doi:10.1016/j.rec.2024.05.006

BibTeX
@article{Tran2025,
  author = {Tran, Fabian and Ruperti-Repilado, Francisco Javier and Haaf, Philip and Lopez-Ayala, Pedro and Greutmann, Matthias and Schwerzmann, Markus and Bouchardy, Judith and Gabriel, Harald and Stambach, Dominik and Schwitter, Juerg and Wustmann, Kerstin and Freese, Michael and Mueller, Christian and Tobler, Daniel},
  title = {NT-proBNP in systemic right ventricles: a new cutoff level for risk stratification?},
  journal = {Revista Española de Cardiología (English Edition)},
  year = {2025},
  doi = {10.1016/j.rec.2024.05.006}
}
Kostenlos starten →